136 patients on hemodialysis, 89 males and 47 females, were studied; we evaluated the index of hepatic function (SGOT and SGPT) and antibodies against HCV. We observed 42 cases of increased transaminases classified as non-A, non-B (NANB) hepatitis. Antibodies against HCV were present in 40 patients. Among 42 patients with NANB hepatitis. 31 (73.8%) presented anti-HCV antibodies. No significant clinical or laboratory difference exists between anti-HCV-positive and -negative patients with NANB hepatitis. The distribution of patients who present anti-HCV antibodies is similar in post-transfusional and sporadic forms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000186903 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Hepatitis C virus infection and hepatocarcinogenesis].
Orv Hetil
September 2010
Semmelweis Egyetem, Altalános Orvostudományi Kar, I. Belgyógyászati Klinika, Budapest.
It is evidenced that both HBV and HCV infections may cause chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). HCV is considered as an oncogen virus. The mechanism of carcinogenesis in case of the two distinct viruses shows a number of common and different features.
View Article and Find Full Text PDFThe history of the "natural history" of hepatitis C (1968-2009).
Liver Int
January 2009
National Institute of Diabetes and Digestive, and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
In the late 1960's, only types A and B hepatitis were believed to exist, distinguished by circumstances of exposure and incubation periods. In the early 1970's, studies of transfusion recipients were begun with the belief that hepatitis B would be responsible should transfusion-associated hepatitis develop. After discovery of the viruses of hepatitis A and B, neither agent was found responsible, hence non-A, non-B (NANB) hepatitis.
View Article and Find Full Text PDFStrategies for assessing the long-term consequences of Hepatitis C virus infection.
Minerva Gastroenterol Dietol
December 2000
National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
The entity of non-A, non-B (NANB) hepatitis was identified in the early 1970's in the course of studies of transfusion-associated hepatitis. It was first thought to be a mild illness because most persons identified with acute hepatitis lacked symptoms, had mild enzyme elevations, and were not jaundiced. It was only after realisation that enzyme elevations persisted in almost all affected persons, and that about 20% of those undergoing liver biopsy showed fibrosis and even cirrhosis, that concern began to grow.
View Article and Find Full Text PDFAssociation of fulminant non-A non-B hepatitis with homozygosity for HLA A1-B8-DR3.
J Gastroenterol Hepatol
April 2005
Gastroenterology Unit and Liver Transplant Unit, Austin Hospital, Heidelberg, Victoria, Australia.
Background: For the majority of cases of acute liver failure in western Europe and North America an etiology cannot be defined. The condition is most often called fulminant non-A, non-B (NANB) hepatitis. Features such as female preponderance and presence of serum autoantibodies suggest a possible autoimmune basis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!